DUBLIN, Sept. 27, 2016 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company today
announced that it has presentations in overactive bladder and
nocturia at the upcoming American Urogynecologic Society (AUGS)
Annual Scientific Meeting in Denver,
Colorado, September 27 - October
1.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
The scheduled times (noted in local Mountain Daylight Time) of
the presentations and room locations at the Colorado Convention Center are as follows:
- "Development of a New Patient Reported Outcomes (PRO) Measure
on the Impact of Nighttime Urination (INTU) in Patients with
Nocturia –Psychometric Evaluation" (in collaboration with
development partner, Serenity Pharmaceuticals LLC)
- Podium Presentation: Paper 19, Four Seasons 4
- Authors: Bennet J, Khalaf K, Banderas B, Abrams S, Cheng L,
Fein S
- Thursday, September
29th 11:15 – 11:25
AM
- "Cost-effectiveness of onabotulinumtoxinA vs. best supportive
care, oral therapies, percutaneous tibial nerve stimulation, and
sacral nerve stimulation for the treatment of overactive bladder
from the US payer perspective"
- Podium Presentation: Paper 36, Four Seasons 1
- Authors: Hessami S, Gultyaev D, Lister J, Khalaf K, Boer
R`
- Friday, September 30th
10:00 – 10:10 AM
- "Long-Term OnabotulinumtoxinA Treatment Results in Consistent,
Durable Improvements in Health-Related Quality Of Life in Patients
with Overactive Bladder"
- Podium Presentation: Paper 39, Four Seasons 1
- Pettit , Magyar A, Nicandro JP, Hale
- Friday, September 30, 10:30 –
10:40 AM
- "The Quality of Life among Women with Nocturia"
- ePoster, available online throughout conference
- Authors: Luber K, Kawahara S, Pulicharam R, Wang D, Burk C
- "Network Meta-Analysis To Assess The Treatment Effect Of
OnabotulinumtoxinA, Mirabegron And Anticholinergics Versus Placebo
For Overactive Bladder"
- ePoster, available online throughout conference
- Authors: Elkadry E, Ginsberg D, McCool R, Glanville J,
Fleetwood K, James D, Khalaf K, Nitti V
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing, manufacturing and
commercializing branded pharmaceuticals, devices and biologic
products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
65+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 15,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what it is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live healthier lives
everyday.
For more information, visit Allergan's website at
www.Allergan.com
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended
June 30, 2016 (such periodic public
filings having been filed under the "Actavis plc" name). Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-to-present-new-data-at-the-american-urogynecologic-society-annual-meeting-in-denver-300334653.html
SOURCE Allergan plc